Spruce Street Capital LP
CIK: 0002050194Latest portfolio: $302.7M · Q4 2025
Holdings
27
Total Value
$302.7M
New Positions
27
Closed Positions
0
Top Holdings
View All 27 Holdings →| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | CDTXCIDARA THERAPEUTICS INC | 232,269 | $51.3M | 16.95% | |
| 2 | RLAYRELAY THERAPEUTICS INC | 2,984,125 | $25.2M | 8.34% | |
| 3 | LBRXLB PHARMACEUTICALS INC | 1,005,593 | $22.4M | 7.40% | |
| 4 | RLMDRELMADA THERAPEUTICS INC | 4,086,181 | $19.7M | 6.52% | |
| 5 | PCVXVAXCYTE INC | 400,360 | $18.5M | 6.10% | |
| 6 | KNSAKINIKSA PHARMACEUTICALS INTL | 434,982 | $17.9M | 5.93% | |
| 7 | EYPTEYEPOINT INC | 981,543 | $17.9M | 5.92% | |
| 8 | YB4PSAVARA INC | 2,411,093 | $14.5M | 4.80% | |
| 9 | ERASERASCA INC | 3,889,632 | $14.5M | 4.78% | |
| 10 | DNTHDIANTHUS THERAPEUTICS INC | 297,437 | $12.3M | 4.05% | |
| 11 | SRZNSURROZEN INC | 432,040 | $9.8M | 3.23% | |
| 12 | OCULOCULAR THERAPEUTIX INC | 783,999 | $9.5M | 3.14% | |
| 13 | SABSSAB BIOTHERAPEUTICS INC | 2,198,502 | $8.2M | 2.72% | |
| 14 | IKTINHIBIKASE THERAPEUTICS INC | 3,581,603 | $7.3M | 2.43% | |
| 15 | ELVNENLIVEN THERAPEUTICS INC | 446,084 | $6.9M | 2.27% | |
| 16 | NERVMINERVA NEUROSCIENCES INC | 1,655,500 | $6.7M | 2.20% | |
| 17 | ABVXABIVAX SA | 49,119 | $6.6M | 2.19% | |
| 18 | HELPCYBIN INC | 770,000 | $6.3M | 2.08% | |
| 19 | KALVKALVISTA PHARMACEUTICALS INC | 387,968 | $6.3M | 2.07% | |
| 20 | ENTAENANTA PHARMACEUTICALS INC | 389,687 | $6.1M | 2.03% | |
| 21 | ANROALTO NEUROSCIENCE INC | 222,844 | $4.0M | 1.31% | |
| 22 | LONAATHIRA PHARMA INC | 393,701 | $3.0M | 0.98% | |
| 23 | CNTACENTESSA PHARMACEUTICALS PLC | 77,997 | $1.9M | 0.64% | |
| 24 | ALECALECTOR INC | 1,117,986 | $1.7M | 0.58% | |
| 25 | LXEOLEXEO THERAPEUTICS INC | 175,000 | $1.7M | 0.57% |
Sector Breakdown
Healthcare0.0% ($2.5245223841973618e+97T)
Unknown0.0% ($5.1T)
Filing History
| Quarter | Filing Date | Portfolio Value | Holdings |
|---|---|---|---|
| Q4 2025 | Feb 13, 2026 | $302.7M | 27 |
Fund Information
Spruce Street Capital LP is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $302.7M across 27 holdings. The largest position is CIDARA THERAPEUTICS INC (CDTX), representing 17.0% of the portfolio. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.